MethodS: Four cases presenting the Department of Emergency Medicine and diagnosed with mad honey intoxication were included in the study. GTX levels in blood, urine, and honey consumed by patients were determined using liquid chromatography-tandem mass spectrometry. reSultS: Patients' mean blood GTX I level was 30.62 ng/mL, GTX III level 4.917 ng/mL, urine GTX I level 0.447 mg/mL, and GTX III level 1.998 mg/mL. The mean GTX I level in the honey samples consumed was 4.683 mg/g and GTX III level 8.423 mg/g. concluSion: The present study is unique in representing the first time that GTXs have been determined in human body fluids. There is now an urgent need for a large series of studies to provide statistical evidence whether there is a relationship between levels of toxins in human body fluids and clinical picture.
T he term "mad honey" results from grayanotoxins (GTXs) in flowers of plants of the genus Rhododendron L (Ericaceae) being mixed in with honey by bees. Species containing the toxin include the purple-flowered Rhododendron ponticum and yellow-flowered R luteum. 1 Due to its toxic effects, researchers have to date concentrated on determining and characterizing GTX in Examination using LC-MS/MS determination of grayanotoxin levels in blood, urine, and honey consumed by patients presenting to the emergency department with mad honey intoxication and relations with clinical data: a preliminary study Ali The purpose of this study was to investigate GTX levels in blood and urine and in honey consumed by patients with mad honey intoxication and to determine whether there is an association with clinical status. We also hope that clarifying the association between amounts of GTXs in the honey consumed and the patient' s clinical status will help establish whether the honey that has been consumed is more or less toxic.
MethodS

Collection of samples
Four cases presenting to Emergency Medicine Clinic and diagnosed with mad honey intoxication were included in the study. Mad honey, blood, and urine samples were obtained from patients intoxicated with GTXs and presenting to the Department of Emergency Medicine at Medical Faculty. GTX levels in patients' blood, urine, and the honey they consumed were examined simultaneously. The blood (5 mL) and urine (5 mL) samples were obtained from patients on presentation to the emergency department. Patients' blood and urine specimens were centrifuged at 12 000 rpm at 5°C. After centrifugation, the supernatants were collected and lyophilized at -50°C overnight, and the dry materials were stored at -80°C for further analysis.
Chemicals and reagents
All chemicals and reagents were of analytical grade. GTX I was obtained from Professor Na of Chungnam National University, Korea. GTX III Hemi (ethyl acetate) adduct (purity, ≥90%) and clindamycin hydrochloride (internal standard, IS) were purchased from Sigma-Aldrich (St Louis, Missouri). The solid-phase extraction (SPE) cartridge (based on the adsorption effect in the reverse mode) and adande:1 PEP (polymer enhanced polymer, 30 mg/mL), were purchased from Shiseido (Tokyo, Japan). HPLC-grade methanol and water were purchased from Fischer Scientific Co. (Fair Lawn, NJ, USA). Analytical reagent-grade glacial acetic acid was purchased from Merck Company (Darmstadt, Germany).
Preparation of GTX standards
The validated method by Cho et al (2014) was followed for preparing GTX standard stock solutions. Standard stock solutions were prepared by dissolving 1 mg of GTX I and I mg of GTX III in 10 mL methanol (v/v), respectively. The stock solution for IS was made by dissolving 1 mg of clindamycin in 10 mL deionized water. Working solutions of GTXs were prepared by serially diluting stock solutions with methanol to required concentrations. IS were prepared by dilution with water to a concentration of 25 ng/mL. Calibration standards were prepared by spiking each 0.05 mL working solution of GTX I and GTX III into 0.5 mL of the blood, urine, or mad honey samples (0.2 g). A fixed amount of IS (25 ng/ mL, 0.05 mL) was added to each sample to achieve a final concentration of 2.5 ng/mL.
Sample preparation
A 0.05-mL aliquot of IS (25 ng/mL), 0.5 mL of phosphate buffer, and 2 mL of acetonitrile were added to a 0.5-mL aliquot of blood sample in cap tubes. Sample blood mixtures were vortex-mixed for 3 minutes and then centrifuged at 10 000g for 5 minutes. The supernatant solution was transferred and evaporated under N 2 at 60°C. The residue was then dissolved in 1 mL of water and vortex-mixed. All the supernatant was loaded onto a cartridge (adande:1 PEP) preconditioned with 1 mL of methanol and 1 mL of water. After complete loading, the cartridge was washed with 1 mL of hexane. GTXs were subsequently eluted with 2 mL of methanol. The eluate was evaporated under N 2 at 60°C. The dried residue was reconstituted in 0.1 mL of 1% acetic acid in methanol. A 0.2-g mad honey sample was precisely weighed into a 10-mL mass flask. Next, 0.025 mL of IS and water were added to make a total sample volume to 10 mL. Next, 0.05 mL of IS and 0.45 mL of phosphate buffer were added to a 0.5-mL urine sample. One milliliter of a well-mixed honey sample or urine sample was loaded onto an SPE cartridge preconditioned with 2 mL of methanol followed by 2 mL of water. After sample loading, the cartridge was eluted with 2 mL of methanol. The eluate was dried under N 2 at 60°C, and the residue was reconstituted in 0.1 mL of 1% acetic acid in methanol.
Aliquots of 5 µL of the clear supernatants were injected into the LC-MS/MS system.
Liquid chromatography and mass spectrometer (MS) conditions
Throughout the analysis, optimized validated high-performance liquid chromatography (HPLC) and LC-MS/ MS working conditions were selected based on a recent publication by Cho et al (2014).
Mass spectrometric detection was performed on a Sciex 3200 QTRAP system (AB Sciex, Concord, Canada) equipped with an electrospray ionization source in positive ion mode. Analyst (version 1.5.1, AB Sciex) software was used for instrument setting, data acquisitions, and processing.
reSultS
Three of the patients presented to the emergency department were male and 1 female. The majority of pa-tients reported that symptoms began 2 hours after consuming honey for male patients and 30 minutes after consuming for female patients. All patients presented with dizziness and nausea; hypotension and bradycardia were present in all subjects in Table 1 .
GTX I and GTX III levels in blood collected from patients presenting to our emergency department due to mad honey poisoning, and levels of these detected in the honey consumed are shown in Table 2 . The highest blood GTX I and GTX III levels were determined in Case 1. The amount of GTX I in the honey consumed by this patient was 0.61 µg/g. This patient' s blood pressure and heart rate at presentation to the emergency department were 60/40 mm Hg and 42 beats/min, respectively.
Although our fourth case consumed only a small amount of honey, the symptoms and signs appeared more quickly, and the highest level of GTX III was also determined in the honey consumed by this patient.
The patients' mean blood GTX I level was 30.62 ng/mL, mean GTX III level was 4.917 ng/mL, mean urine GTX I was 0.447 µg/mL, and mean GTX III level was 1.998 µg/mL. The mean GTX I level in the honey consumed was 4.683 µg/g and the mean GTX III level was 8.423 µg/g. The patients' mean blood pressure was 77.5/47.5 mm Hg and mean heart rate was 38 beats/min.
diScuSSion
The most common symptoms in Mad honey intoxication are pronounced hypotension and bradycardia.1 Other common symptoms are sweating, stupor, altered mental state, syncope, diplopia, blurred vision, and hypersalivation. 3 The mean amount of honey consumed in mad honey intoxications has been reported at 5 to 30 g. Symptoms begin 1.5 to 3 hours after consumption. 4 Intoxicated patients generally exhibit improvement with support therapy, with saline solution and 1 to 2 mg of intravenous atropine. Patients are discharged 2 to 6 hours after cardiac monitoring in mild intoxications, while symptoms disappear after 24 hours at latest in more severe cases. 1 It is generally very difficult to estimate statuses in patients presenting with "mad honey" intoxication. Which patients should be hospitalized and which monitored on an outpatient basis is, therefore, a significant problem that physicians are facing. 5 Knowing the amount of toxin in blood, urine, and honey consumed can be Table 1 . Patients' gender, time of onset of symptoms after honey consumption, amount of mad honey consumed, blood pressure, and heart rate. data belong to patients presenting to the department of emergency Medicine at a university hospital (turkey) with mad honey intoxication. important to provide a relation between levels of toxins in human body fluids and clinical picture. No previous studies have investigated blood and urine specimens and honey consumed by patients with such intoxications. The determination of GTXs was first achieved in some biological samples including feces, rumen, and urine (Holstege et al 2001) . The difference of origin of the biological samples, and extraction and isolation of GTXs from these samples, owing to the lack of analytical sensitivity and low selectivity, required a complicated sample pretreatment procedure for extraction and purification. 2 This uncertainty in the sampling, detection, and quantification of GTXs using blood samples was eliminated by Cho et al (2014), who for the first time developed a sensitive, reliable, and validated quantitative LC-MS/MS method in rat whole blood. 6 In the present study, methods described by Cho et al (2014) were applied to blood samples from the 4 cases presenting with mad honey intoxication to our emergency department. Samples of the mad honey responsible were also analyzed in parallel.
No significant correlations were determined between gender, time of onset of symptoms after honey consumption, amount of mad honey consumed, blood pressure or heart rate, and GTX I and GTX III contents, and several reasons may be attributed to this fact: (a) it may be due to age differences between the patients, the distances involved, geographical variation between the honey sources, and unequal gender distribution among the patients. (b) The distribution and abundance of the Rhododendron species, R ponticum, and R luteum are quite heterogenous at the altitudes (Table 1) where the mad honey that caused intoxication was produced. This variation may affect GTX concentrations in nectar composition, and thus mad honey composition. (c) Variations in onset time and GTX concentrations mainly result from the speed of absorption as well as blood concentrations of GTX. (d) Large quantities of honey may disturb the absorption of GTX. Onset time may, therefore, be delayed. Another possible reason is that "mad honey" contains above 20 analogues. We along with other study groups detected only 2 or 3 kinds of GTXs. These difficulties can be resolved by providing GTX standards from the analogues as working standards.
In conclusion, this is a preliminary study, and the first to show GTX levels in specimens from human body fluids. No statistical comparison could be performed, as the case numbers were limited. There is now an urgent need for large series studies to provide statistical evidence whether there is a relation between levels of toxins in human body fluids and clinical picture. The research value of the present study lies in determining and quantifying GTXs obtained from human body samples, blood, and urine, and would assist researchers interested in GTXs in terms of forensics and clinical toxicology.
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